Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study
Publication
, Conference
Altman, JK; Perl, AE; Cortes, JE; Levis, MJ; Smith, CC; Litzow, MR; Baer, MR; Claxton, DF; Erba, HP; Gill, SC; Goldberg, SL; Jurcic, JG ...
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Altman, J. K., Perl, A. E., Cortes, J. E., Levis, M. J., Smith, C. C., Litzow, M. R., … Bahceci, E. (2015). Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Altman, Jessica K., Alexander E. Perl, Jorge E. Cortes, Mark J. Levis, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, et al. “Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Altman JK, Perl AE, Cortes JE, Levis MJ, Smith CC, Litzow MR, et al. Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Altman, Jessica K., et al. “Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Altman JK, Perl AE, Cortes JE, Levis MJ, Smith CC, Litzow MR, Baer MR, Claxton DF, Erba HP, Gill SC, Goldberg SL, Jurcic JG, Larson RA, Lui C, Ritchie EK, Sargent B, Schiller GJ, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart RK, Baldus CD, Rollig C, Neubauer A, Martinelli G, Bahceci E. Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology